awmsg logo



midodrine hydrochloride (Bramox®)


Reference No. 2650

Publication date:
18/11/2015


Appraisal information

midodrine hydrochloride (Bramox®) 2.5 mg tablet
midodrine hydrochloride (Bramox®) 5 mg tablet


Company: Brancaster Pharma Ltd
BNF category: Cardiovascular system
NMG meeting date: 09/09/2015
AWMSG meeting date: 21/10/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2915
Ministerial ratification: 17/11/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Midodrine hydrochloride (Bramox®) is recommended for use within NHS Wales for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download